ABVC
ABVC BIOPHARMA, INC.
$1.19
-9.16%
$30.9M
No data for this timeframe.
Vol
Market Cap$30.9M
Cap SizeNano Cap
Inst. Holders7 funds
Inst. Value$508.8K
Inst. Activity4 buys / 0 sells
SEC Reports1
Recent Activity
Mar 3, 2026
SEC
ABVC BioPharma disclosed a restatement of its Q3 2025 financial statements due to improper revenue recognition of $795,9
8-K — Impact 8/10
Inst.
VANGUARD GROUP INC — DOUBLED
267,450 shares ($813.0K)
Inst.
RENAISSANCE TECHNOLOGIES LLC — DOUBLED
110,500 shares ($335.9K)
Apr 28, 2026
earnings_calendar
ABVC Q1 2026 Earnings Scheduled — 2026-04-28
Analyst Ratings
0Strong Buy
0Buy
3Hold
1Sell
2Strong Sell
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| ROYAL BANK OF CANADA | — | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $184.9K | — |
| VANGUARD FIDUCIARY TRUST CO | $94.4K | — |
| RENAISSANCE TECHNOLOGIES LLC | $92.3K | DOUBLED |
| STATE STREET CORP | $70.6K | DOUBLED |
7 institutional holders with $508.8K total value (524,523 shares) as of 2026-Q1. Top holders: ROYAL, VANGUARD, VANGUARD.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | ROYAL BANK OF CANADA | 17 | $0.00 | 0.0% | — |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 190,574 | $184.9K | 36.3% | — |
| 3 | VANGUARD FIDUCIARY TRUST CO | 97,363 | $94.4K | 18.6% | — |
| 4 | RENAISSANCE TECHNOLOGIES LLC | 95,100 | $92.3K | 18.1% | DOUBLED +164.9% |
| 5 | STATE STREET CORP | 72,800 | $70.6K | 13.9% | DOUBLED +464.3% |
| 6 | BlackRock, Inc. | 56,442 | $54.8K | 10.8% | — |
| 7 | DIMENSIONAL FUND ADVISORS LP | 12,227 | $11.9K | 2.3% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | DOUBLED | 111,533 | 267,450 | +139.8% | $813.0K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 41,706 | 110,500 | +164.9% | $335.9K | 2025-Q3 |
| STATE STREET CORP | DOUBLED | 12,900 | 72,800 | +464.3% | $221.3K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 133 | 175 | +31.6% | $532.00 | 2025-Q3 |
| VANGUARD GROUP INC | DOUBLED | 46,947 | 111,533 | +137.6% | $248.2K | 2025-Q2 |
| UBS Group AG | DOUBLED | 10 | 29,003 | +289930.0% | $30.7K | 2025-Q1 |
| BANK OF AMERICA CORP /DE/ | TRIM | 256 | 78 | -69.5% | $53.00 | 2024-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
1 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 0 neutral. Avg impact: 8.0/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 0% buy across 6 analysts — 0 strong buy, 0 buy, 3 hold, 1 sell, 2 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2023-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2023-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Oct 1, 2023 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Sep 1, 2023 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Aug 1, 2023 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Jul 1, 2023 | 0 | 0 | 3 | 1 | 2 | 0% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 6, 2026
Clinical Trial
PDC-1421 Treatment in Adult Patients With ADHD
Phase Phase 2 — COMPLETED
Apr 28, 2026
earnings_calendar
ABVC Q1 2026 Earnings Scheduled — 2026-04-28
Apr 13, 2026
earnings_calendar
ABVC Q4 2025 Earnings After Market Close — 2026-04-13